SR1 assays of alpha-fetoprotein, carcinoembryonic antigen, and prostate-specific antigen compared with corresponding established commercial assays

Abstract We compared results obtained with the newly developed alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and prostate-specific antigen (PSA) assays for the fully-automated Serono SR1 analyzer with those obtained with the major, established methods for these analytes: Serono Serozyme and Bridge, Abbott IMx, Kodak Amerlite, Boehringer Mannheim ES600, Pharmacia Delfia, Hybritech Tandem-E and Tandem-R, Ciba Corning ACS180, and DPC IRMA-Count. The correlations were good for all methods studied (r > or = 0.94). For AFP, numerical agreement was good, with linear regression slopes of 0.88 to 1.15; for CEA, correlation slopes of 1.03 to 1.16 were observed. The SR1 PSA assay agreed well with five of the seven methods studied (slopes of 0.98 to 1.22), but the Ciba Corning ACS180 PSA assay gave results higher than all other methods studied (slope 0.54 vs SR1 at low doses) and the Abbott IMx PSA assay gave results lower than all other methods studied (slope 1.47 vs SR1).

Download Full-text

Carcinoembryonic Antigen, Alpha-fetoprotein, and Prostate-Specific Antigen in the Sera of Industrial Workers Exposed to Phenol, Formaldehyde, Urea, and Mixed Vapors

Inhalation Toxicology ◽

10.1080/08958370600904603 ◽

2006 ◽

Vol 18 (13) ◽

pp. 1041-1046 ◽

Cited By ~ 5

Author(s):

Mohamed El Far ◽

M. El Naggar ◽

Om Ali Y. Elkhawaga ◽

Raida Yahya ◽

Asmaa Allam ◽

...

Keyword(s):

Carcinoembryonic Antigen ◽

Prostate Specific Antigen ◽

Phenol Formaldehyde ◽

Specific Antigen ◽

Alpha Fetoprotein ◽

Industrial Workers

Download Full-text

Inappropriate practice in tumor marker requests at a university hospital in Western Saudi Arabia: A 3-year retrospective study

The International Journal of Biological Markers ◽

10.1177/1724600820971305 ◽

2020 ◽

Vol 35 (4) ◽

pp. 35-43

Author(s):

Jamil A. Al-Mughales ◽

Mahmood Shaheen Alahwal

Keyword(s):

Tumor Marker ◽

Carcinoembryonic Antigen ◽

Prostate Specific Antigen ◽

Clinical Picture ◽

Specific Antigen ◽

Alpha Fetoprotein ◽

University Hospital ◽

Prescribing Pattern ◽

Inappropriate Use ◽

Total Prostate Specific Antigen

Objectives: This study assessed the level of appropriateness of tumor marker requests in a teaching hospital and estimated the financial cost associated with inappropriate use. Methods: A retrospective review of patients’ electronic records was conducted over a 3-year period (2015–2017) for tumor marker requests, including carcinoembryonic antigen, alpha-fetoprotein, cancer antigen (CA)15-3, CA125, CA19-9, and total and free prostate-specific antigen (PSA and fPSA), along with the associated clinical data that motivated the requests. Inappropriate use was defined as tumor marker requests without any relevant clinical picture. Costs due to inappropriate tumor marker requests were estimated based on the unit costs applied in the institution. Results: A total of 7128 patients had at least one tumor marker request between 2015 and 2017. The clinical picture that motivated tumor marker requests was absent in 71.5%, while 12.9% of the requests were associated with a malignancy. The most frequent prescribing pattern was total prostate-specific antigen alone (2128; 29.9%), followed by alpha-fetoprotein alone (1185; 16.6%), and carcinoembryonic antigen alone (506; 7.1%). Year-over-year analysis revealed an increasing tendency in requesting carcinoembryonic antigen and CA15-3. The rate of inappropriate use varied by tumor marker and ranged between 56.4% for fPSA and 86.8% for total prostate-specific antigen. The overall costs due to inappropriate tumor marker requests were estimated at $2,785,493 over the 3 years, representing an average of $0.93 million per year. Conclusion: Inappropriate use of tumor marker requests is a major issue regarding its high prevalence and the considerable associated costs. The role of laboratories in the management of tumor marker requests should be emphasized.

Download Full-text

Evaluation of MARK BTM for Quantitative Measurement of Three Tumor Markers: Prostate Specific Antigen, Alpha Fetoprotein, and Carcinoembryonic Antigen

Clinical Laboratory ◽

10.7754/clin.lab.2019.190130 ◽

2019 ◽

Vol 65 (08/2019) ◽

Author(s):

Hyundoo Hwang ◽

Jaesik Kim ◽

Jaekyu Choi ◽

Kil Kim ◽

Ho-Seong Han

Keyword(s):

Carcinoembryonic Antigen ◽

Prostate Specific Antigen ◽

Tumor Markers ◽

Quantitative Measurement ◽

Specific Antigen ◽

Alpha Fetoprotein

Download Full-text

Variation in measurement of prostate-specific antigen: importance of method and lot variability

Clinical Chemistry ◽

10.1093/clinchem/41.12.1730 ◽

1995 ◽

Vol 41 (12) ◽

pp. 1730-1737 ◽

Cited By ~ 20

Author(s):

M H Wener ◽

P R Daum ◽

M K Brawer

Keyword(s):

Linear Regression ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Free Psa ◽

Regression Slopes

Abstract Equivalence between Hybritech Tandem and Abbott IMx PSA methods have been reported by some but not all previous investigators. To determine reasons for these differing conclusions, we measured serum PSA with three different lots each of IMx and Tandem-E kits. Overall, mean IMx results were significantly lower than Tandem-E results; however, for selected sera, the IMx results were consistently higher than the Tandem-E results. Lot-to-lot differences for the IMx method were significantly greater than those with the Tandem-E method. Most IMx/Tandem-E lot-to-lot comparisons had linear regression slopes that differed significantly from 1.0, but some did not. Conclusions concerning the equivalence of the IMx and the Tandem-E methods can be influenced both by variations in the proportions of free PSA in sera in tested populations and by lot-to-lot differences in the IMx method.

Download Full-text